Ajovy
Provider 
Founded 1901
Sells To Consumers, Enterprise
Pricing Model Recurring, Software, Transactional
Ownership Public

Ajovy (fremanezumab-vfrm) is Teva's subcutaneous CGRP monoclonal antibody indicated for the preventive treatment of migraine in adults.
Ajovy is Teva Pharmaceutical Industries' fremanezumab-vfrm, a monoclonal antibody targeting CGRP administered by subcutaneous injection for the preventive treatment of migraine in adults, with a consumer-facing site covering dosing and support services.
As a marketed CGRP preventive it belongs to the same prophylaxis segment AgoneX Biopharmaceuticals' AGX-201 program addresses through histamine receptor modulation.
| Attribute | Ajovy | AGX-201 | |
|---|---|---|---|
| Provider | |||
| Founded | 1901 | 2011 | |
| Sells To | Consumers, Enterprise | Enterprise | |
| Pricing Model | Recurring, Software, Transactional | Recurring, Software | |
| Ownership | Public | Private |
Provider 
Founded 1901
Sells To Consumers, Enterprise
Pricing Model Recurring, Software, Transactional
Ownership Public
Provider 
Founded 2011
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private
Emgality (galcanezumab-gnlm) is Eli Lilly's subcutaneous CGRP monoclonal antibody indicated for the preventive treatment of migraine in adults.


Nurtec ODT is a Pfizer oral gepant for acute migraine treatment and episodic migraine prevention.

Vyepti (eptinezumab-jjmr) is Lundbeck's intravenous CGRP monoclonal antibody indicated for the preventive treatment of migraine in adults.

Emgality (galcanezumab-gnlm) is Eli Lilly's subcutaneous CGRP monoclonal antibody indicated for the preventive treatment of migraine in adults.

Nurtec ODT is a Pfizer oral gepant for acute migraine treatment and episodic migraine prevention.

Qulipta (atogepant) is AbbVie's once-daily oral CGRP receptor antagonist indicated for the preventive treatment of migraine in adults.
